Compare HDL & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HDL | FTRE |
|---|---|---|
| Founded | 2016 | 1996 |
| Country | Singapore | United States |
| Employees | 14003 | N/A |
| Industry | Restaurants | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 829.7M | 829.3M |
| IPO Year | N/A | 2023 |
| Metric | HDL | FTRE |
|---|---|---|
| Price | $13.41 | $14.98 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $14.06 |
| AVG Volume (30 Days) | 2.3K | ★ 1.5M |
| Earning Date | 05-20-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,723,400,000.00 |
| Revenue This Year | $14.73 | N/A |
| Revenue Next Year | $12.94 | $3.09 |
| P/E Ratio | $55.56 | ★ N/A |
| Revenue Growth | N/A | ★ 1.00 |
| 52 Week Low | $13.31 | $3.97 |
| 52 Week High | $23.62 | $18.67 |
| Indicator | HDL | FTRE |
|---|---|---|
| Relative Strength Index (RSI) | 38.04 | 74.00 |
| Support Level | $13.31 | $8.85 |
| Resistance Level | $15.40 | $18.26 |
| Average True Range (ATR) | 0.24 | 0.88 |
| MACD | -0.01 | 0.52 |
| Stochastic Oscillator | 4.59 | 81.71 |
Super Hi International Holding Ltd is an investment holding company, and its subsidiaries are principally engaged in restaurant operations, delivery business, and sales of hot pot condiment products and food ingredients located in the overseas market outside Mainland China, Hong Kong, Macau, and Taiwan. Its mission is to become a world-wide integrated restaurant group, build the world's Chinese cuisine brand, and promote Chinese culinary heritage world-wide.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.